Summary
Thermo Fisher Scientific Inc. reported strong revenue growth for the three and six months ended June 28, 2014, largely driven by the significant acquisition of Life Technologies Corporation in February 2014. This acquisition substantially increased total assets and liabilities, particularly goodwill and long-term obligations. While revenue saw a substantial year-over-year increase, operating income and margins experienced a decline due to integration costs, higher amortization expenses related to the acquisition, and restructuring charges. The company also divested certain businesses, notably the sera and media, gene modulation, and magnetic beads businesses to GE Healthcare, as a condition for regulatory approval of the Life Technologies acquisition. This divestiture resulted in a significant gain. Management expects that existing cash, future cash flow from operations, proceeds from anticipated divestitures, and available credit facilities will be sufficient to meet financial obligations for the foreseeable future. Investors should note the substantial increase in debt and acquisition-related intangible assets and goodwill on the balance sheet. While revenue growth is positive, the impact of integration costs and amortization on profitability requires careful monitoring. The company's strategic focus remains on integrating Life Technologies and continuing to expand its offerings across its various segments.
Financial Highlights
56 data points| Revenue | $4.32B |
| Cost of Revenue | $2.11B |
| Gross Profit | $1.85B |
| R&D Expenses | $183.70M |
| SG&A Expenses | $1.25B |
| Operating Expenses | $3.97B |
| Operating Income | $348.10M |
| Interest Expense | $129.10M |
| Net Income | $278.50M |
| EPS (Basic) | $0.70 |
| EPS (Diluted) | $0.69 |
| Shares Outstanding (Basic) | 399.40M |
| Shares Outstanding (Diluted) | 403.10M |
Key Highlights
- 1Significant revenue increase, primarily driven by the acquisition of Life Technologies Corporation (completed February 3, 2014) for $15.30 billion.
- 2Consolidated assets and liabilities grew substantially due to the Life Technologies acquisition, with Goodwill increasing from $12.5 billion to $19.4 billion and Acquisition-related Intangible Assets from $7.1 billion to $15.6 billion.
- 3The company completed the divestiture of its sera and media, gene modulation, and magnetic beads businesses to GE Healthcare for $1.05 billion, generating a pre-tax gain of approximately $761 million.
- 4Operating income decreased to $348.1 million from $375.4 million for the quarter and increased to $1.22 billion from $762.5 million for the six-month period, impacted by acquisition-related costs and amortization.
- 5The Life Sciences Solutions segment, significantly bolstered by the Life Technologies acquisition, saw its revenue jump from $181.0 million to $1,103.1 million for the quarter.
- 6Long-term obligations increased significantly, reaching $12.5 billion from $9.5 billion at year-end 2013, largely due to debt financing for the Life Technologies acquisition.
- 7The company continues to incur restructuring and other costs, particularly related to integrating Life Technologies, with $232 million recognized in Q2 2014.